Summary of research progress on postoperative thyroid stimulating hormone suppression therapy of low-risk differentiated thyroid cancer
10.3760/cma.j.cn115396-20240809-0025
- VernacularTitle:低危分化型甲状腺癌术后促甲状腺素抑制治疗的研究进展
- Author:
Yadi WANG
1
;
Wenjie DAI
Author Information
1. 哈尔滨医科大学附属第一医院甲状腺外科，哈尔滨 150001
- Keywords:
Thyroid neoplasms;
Thyrotropin;
Differentiation
- From:
International Journal of Surgery
2024;51(9):644-648
- CountryChina
- Language:Chinese
-
Abstract:
At present, the main treatment for differentiated thyroid carcinoma (DTC) in clinical practice is surgery combined with 131I therapy and TSH suppression therapy. The view that TSH suppression therapy after DTC surgery can significantly reduce the recurrence rate of tumors by initially controlling TSH in high-risk patients below 0.1 mU/L has become a widely accepted clinical practice. However, there is no significant additional benefit from excessive TSH suppression in low-risk patients. Currently, there is still controversy in clinical practice regarding the optimal degree of TSH suppression, whether to perform TSH suppression therapy, and the appropriate timing for TSH suppression therapy in middle-low-risk patients. Moreover, long-term TSH suppression therapy after surgery also brings many side effects. Therefore, this review will summarize the rational use of drugs, adjustment of drug dosage, and individualized TSH suppression therapy plan for low-risk DTC patients after surgery.
